CoChat

An in vitro toolbox to accelerate anti-malarial drug discovery and development

Open access
Charman, Susan A., Andreu, Alice, Barker, Helena, Blundell, Scott, Campbell, Anna, Campbell, Michael, Chen, Gong, Chiu, Francis C. K., Crighton, Elly, Katneni, Kasiram, Morizzi, Julia, Patil, Rahul, Pham, Thao, Ryan, Eileen, Saunders, Jessica, Shackleford, David M., White, Karen L., Almond, Lisa, Dickins, Maurice, Smith, Dennis A., Moehrle, Joerg J., Burrows, Jeremy N., Abla, Nada · 2020 · Malaria Journal
Cited by 149

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background: Modelling and simulation are being increasingly utilized to support the discovery and development of new anti-malarial drugs. These approaches require reliable in vitro data for physicochemical properties, permeability, binding, intrinsic clearance and cytochrome P450 inhibition. This work was conducted to generate an in vitro data toolbox using standardized methods for a set of 45 anti-malarial drugs and to assess changes in physicochemical properties in relation to changing target product and candidate profiles. Methods: Ionization constants were determined by potentiometric titration and partition coefficients were measured using a shake-flask method. Solubility was assessed in biorelevant media and permeability coefficients and efflux ratios were determined using Caco-2 cell monolayers. Binding to plasma and media proteins was measured using either ultracentrifugation or rapid equilibrium dialysis. Metabolic stability and cytochrome P450 inhibition were assessed using human liver microsomes. Sample analysis was conducted by LC–MS/MS. Results: Both solubility and fraction unbound decreased, and permeability and unbound intrinsic clearance increased, with increasing Log D 7.4. In general, development compounds were somewhat more lipophilic than legacy drugs. For many compounds, permeability and protein binding were challenging to assess and both required the use of experimental conditions that minimized the impact of non-specific binding. Intrinsic clearance in human liver microsomes was varied across the data set and several compounds exhibited no measurable substrate loss under the conditions used. Inhibition of cytochrome P450 enzymes was minimal for most compounds. Conclusions: This is the first data set to describe in vitro properties for 45 legacy and development anti-malarial drugs. The studies identified several practical methodological issues common to many of the more lipophilic compounds and highlighted areas which require more work to customize experimental conditions for compounds being designed to meet the new target product profiles. The dataset will be a valuable tool for malaria researchers aiming to develop PBPK models for the prediction of human PK properties and/or drug–drug interactions. Furthermore, generation of this comprehensive data set within a single laboratory allows direct comparison of properties across a large dataset and evaluation of changing property trends that have occurred over time with changing target product and candidate profiles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12936-019-3075-5

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 70

  1. WHO. World malaria report 2015. Geneva: World Health Organization; 2015.
  2. WHO. World malaria report 2018. Geneva: World Health Organization; 2018.
  3. Alonso P, Noor AM. The global fight against malaria is at crossroads. Lancet. 2017;390:2532–4. · DOI
  4. Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14:424–42. · DOI · Paper page
  5. Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, et al. Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica. 2012;42:94–106. · DOI · Paper page
  6. Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, Part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 2011;100:4074–89. · DOI
  7. Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the US Food and Drug Administration’s Office of Clinical Pharmacology. J Pharm Sci. 2019;108:21–5. · DOI · Paper page
  8. Andrews KA, Wesche D, McCarthy J, Mohrle JJ, Tarning J, Phillips L, et al. Model-informed drug development for malaria therapeutics. Annu Rev Pharmacol Toxicol. 2018;58:567–82. · DOI
  9. Jimenez-Diaz MB, Mulet T, Viera S, Gomez V, Garuti H, Ibanez J, et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother. 2009;53:4533–6. · DOI · Paper page
  10. Engwerda CR, Minigo G, Amante FH, McCarthy JS. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 2012;28:515–21. · DOI
  11. McCarthy JS, Marquart L, Sekuloski S, Trenholme K, Elliott S, Griffin P, et al. Linking murine and human Plasmodium falciparum challenge models in a translational path for antimalarial drug development. Antimicrob Agents Chemother. 2016;60:3669–75. · doi:10.1128/aac.02883-15
  12. McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS ONE. 2011;6:e21914. · DOI · Paper page
  13. Stanisic DI, McCarthy JS, Good MF. Controlled human malaria infection: applications, advances, and challenges. Infect Immun. 2018;86:e00479–517. · DOI
  14. Krause A, Dingemanse J, Mathis A, Marquart L, Mohrle JJ, McCarthy JS. Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects. Br J Clin Pharmacol. 2016;82:412–21. · DOI
  15. McCarthy JS, Baker M, O’Rourke P, Marquart L, Griffin P, Hooft van Huijsduijnen R, Mohrle JJ. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. J Antimicrob Chemother. 2016;71:2620–7. · DOI
  16. McCarthy JS, Lotharius J, Ruckle T, Chalon S, Phillips MA, Elliott S, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human Phase 1a/1b randomised study. Lancet Infect Dis. 2017;17:626–35. · DOI
  17. McCarthy JS, Ruckle T, Djeriou E, Cantalloube C, Ter-Minassian D, Baker M, et al. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malar J. 2016;15:469. · doi:10.1186/s12936-016-1511-3
  18. FDA Guidance for Industry. Clinical drug interaction studies - study design, data analysis and clinical implications. Silver Spring: Food Drug Administration; 2017.
  19. Albert A, Serjeant EP. The determination of ionization constants. London: Chapman and Hall; 1984. · DOI · Paper page
  20. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 2008;25:1663–76. · DOI · Paper page
  21. Katneni K, Pham T, Saunders J, Chen G, Patil R, White KL, et al. Using human plasma as an assay medium in Caco-2 studies improves mass balance for lipophilic compounds. Pharm Res. 2018;35:210. · DOI
  22. Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci. 2010;99:4940–54. · DOI · Paper page
  23. Dahlgren D, Roos C, Sjogren E, Lennernas H. Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods. J Pharm Sci. 2015;104:2702–26. · DOI
  24. Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37:1015–51. · DOI · Paper page
  25. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T. Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci. 2004;93:847–54. · doi:10.1002/jps.20012
  26. Plise EG, Tran D, Salphati L. Semi-automated protein binding methodology using equilibrium dialysis and a novel mixed-matrix cassette approach. J Pharm Sci. 2010;99:5070–8. · DOI
  27. Shackleford DM, Jamsen KM. Quantifying uncertainty in the ratio of two measured variables: a recap and example. J Pharm Sci. 2016;105:3462–3. · doi:10.1016/j.xphs.2016.07.019
  28. Di L, Breen C, Chambers R, Eckley ST, Fricke R, Ghosh A, et al. Industry perspective on contemporary protein-binding methodologies: considerations for regulatory drug–drug interaction and related guidelines on highly bound drugs. J Pharm Sci. 2017;106:3442–52. · DOI
  29. Riccardi K, Cawley S, Yates PD, Chang C, Funk C, Niosi M, et al. Plasma protein binding of challenging compounds. J Pharm Sci. 2015;104:2627–36. · DOI
  30. Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos. 2002;23:327–38. · DOI · Paper page
  31. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004;32:647–60. · DOI · Paper page
  32. Settimo L, Bellman K, Knegtel RM. Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharm Res. 2014;31:1082–95. · DOI · Paper page
  33. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 2002;19:1400–16. · DOI · Paper page
  34. van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003;2:192–204. · DOI · Paper page
  35. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;175:880–5. · DOI · Paper page
  36. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents Chemother. 2006;50:3504–6. · DOI
  37. Senarathna SM, Page-Sharp M, Crowe A. The interactions of P-Glycoprotein with antimalarial drugs, including substrate affinity, inhibition and regulation. PLoS ONE. 2016;11:e0152677. · DOI
  38. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54. · DOI · Paper page
  39. Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem. 1996;236:302–8. · DOI · Paper page
  40. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975;65:42–9. · DOI · Paper page
  41. McIntosh MP, Porter CJ, Wasan KM, Ramaswamy M, Charman WN. Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid. J Pharm Sci. 1999;88:378–84. · DOI
  42. Curran RE, Claxton CR, Hutchison L, Harradine PJ, Martin IJ, Littlewood P. Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding. Drug Metab Dispos. 2011;39:551–7. · DOI
  43. Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos. 2004;32:973–82. · DOI · Paper page
  44. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10:197–208. · DOI · Paper page
  45. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26. · DOI · Paper page
  46. Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol. 2011;24:1420–56. · DOI · Paper page
  47. Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov. 2010;5:235–48. · DOI · Paper page
  48. Smith DA, Allerton C, Kalgutkar AS, van de Waterbeemd H, Walker DK, editors. Pharmacokinetics and metabolism in drug design. 3rd ed. Weinheim: Wiley; 2012.
  49. Rosenberger J, Butler J, Dressman J. A refined developability classification system. J Pharm Sci. 2018;107:2020–32. · DOI
  50. Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16:26. · DOI · Paper page
  51. Frampton JE. Tafenoquine: first global approval. Drugs. 2018;78:1517–23. · doi:10.1007/s40265-018-0979-2
  52. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA. 2011;108:4400–5. · DOI · Paper page
  53. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004;430:900–4. · DOI · Paper page
  54. Lindegardh N, Hanpithakpong W, Kamanikom B, Pattayaso J, Singhasivanon P, White NJ, Day NP. Quantification of dihydroartemisinin, artesunate and artemisinin in human blood: overcoming the technical challenge of protecting the peroxide bridge. Bioanalysis. 2011;3:1613–24. · DOI
  55. Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PLM, Craft JC, Arbe-Barnes S, et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol. 2013;75:524–48. · DOI
  56. Salim M, Khan J, Ramirez G, Clulow AJ, Hawley A, Ramachandruni H, Boyd BJ. Interactions of artefenomel (OZ439) with milk during digestion: insights into digestion-driven solubilization and polymorphic transformations. Mol Pharm. 2018;15:3535–44. · DOI
  57. Zientek MA, Youdim K. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos. 2015;43:163–81. · DOI
  58. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos. 2009;37:1355–70. · DOI · Paper page
  59. White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57:5792–807. · DOI
  60. Smith DA, Beaumont K, Maurer TS, Di L. Volume of distribution in drug design. J Med Chem. 2015;58:5691–8. · DOI
  61. Smith DA, Beaumont K, Maurer TS, Di L. Clearance in drug design. J Med Chem. 2019;62:2245–55. · DOI · Paper page
  62. Baragana B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522:315–20. · DOI · Paper page
  63. Phillips MA, White KL, Kokkonda S, Deng X, White J, El Mazouni F, et al. A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria. ACS Infect Dis. 2016;2:945–57. · doi:10.1021/acsinfecdis.6b00144
  64. Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med. 2015;7:296ra111. · DOI · Paper page
  65. Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Silver Spring: U.S. Food and Drug Administration; 2015.
  66. O’Neill PM, Amewu RK, Charman SA, Sabbani S, Gnadig NF, Straimer J, et al. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nat Commun. 2017;8:15159. · DOI
  67. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 1998;58:645–9. · DOI · Paper page
  68. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol. 1984;17:441–6. · DOI · Paper page
  69. Na-Bangchang K, Krudsood S, Silachamroon U, Molunto P, Tasanor O, Chalermrut K, et al. The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J Trop Med Public Health. 2004;35:575–82.
  70. Saha N, Moehrle JJ, Zutshi A, Sharma P, Kaur P, Iyer SS. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. J Clin Pharmacol. 2014;54:386–93. · DOI

Cited by

See all 149

Metadata

Authors
Charman, S. A., Andreu, A., Barker, H., Blundell, S., Campbell, A., Campbell, M., Chen, G., Chiu, F. C. K., Crighton, E., Katneni, K., Morizzi, J., Patil, R., Pham, T., Ryan, E., Saunders, J., Shackleford, D. M., White, K. L., Almond, L., Dickins, M., Smith, D. A., Moehrle, J. J., Burrows, J. N., & Abla, N.
Venue
Malaria Journal
Published
2020-01-02
Volume
19
Issue
1
Pages
1-1
ISSN
1475-2875 (ISSN-L)
OpenAlex
W2998300869
Cited by
149
References
11
FWCI
15.49
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An in vitro toolbox to accelerate anti-malarial drug discovery and development. https://app.cochat.ai/papers/10.1186/s12936-019-3075-5
The paper
Charman, S. A., Andreu, A., Barker, H., Blundell, S., Campbell, A., Campbell, M., Chen, G., Chiu, F. C. K., Crighton, E., Katneni, K., Morizzi, J., Patil, R., Pham, T., Ryan, E., Saunders, J., Shackleford, D. M., White, K. L., Almond, L., Dickins, M., . . . Abla, N. (2020). An in vitro toolbox to accelerate anti-malarial drug discovery and development. Malaria Journal. https://doi.org/10.1186/s12936-019-3075-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.